Instil Bio, Inc. (TIL)
NASDAQ: TIL · Real-Time Price · USD
26.97
+0.14 (0.52%)
Aug 13, 2025, 4:00 PM - Market closed
Instil Bio Employees
Instil Bio had 14 employees as of December 31, 2024. The number of employees decreased by 35 or -71.43% compared to the previous year.
Employees
14
Change (1Y)
-35
Growth (1Y)
-71.43%
Revenue / Employee
n/a
Profits / Employee
-$6,036,429
Market Cap
176.92M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 14 | -35 | -71.43% |
Dec 31, 2023 | 49 | -143 | -74.48% |
Dec 31, 2022 | 192 | -220 | -53.40% |
Dec 31, 2021 | 412 | 262 | 174.67% |
Dec 31, 2020 | 150 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
TIL News
- 1 day ago - Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 14 days ago - ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China - GlobeNewsWire
- 6 weeks ago - Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors - GlobeNewsWire
- 2 months ago - Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program - GlobeNewsWire
- 2 months ago - Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer - GlobeNewsWire
- 2 months ago - Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Instil Bio: Second-Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF Success - Seeking Alpha
- 2 months ago - Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago - GlobeNewsWire